Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy

Huang, Shu‐Pin; Bao, Bo‐Ying; Wu, Ming Tsang; Choueiri, Toni K.; Goggins, William B.; Huang, Chao-Yuan; Pu, Yeong-Shiau; Yu, Chia‐Cheng; Huang, Chun‐Hsiung

doi:10.1002/pros.21334

Cited by 63 publications

(86 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have demonstrated that Gleason scores and PSA levels are associated with the severity of clinical outcome. Huang et al (29) reported that the initial PSA level, a PSA nadir of ≥2 ng/ml and shorter time to PSA nadir were associated with disease progression. Furthermore, Chen et al (30) showed that initial level of PSA was a potential predictive factor for biochemical progression.…”

Section: A B Cmentioning

confidence: 99%

Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma

Yunjuan

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Recent studies have revealed that alternatively activated macrophages (AAMs) are involved in tumor progression. However, the effect of AAMs on the metastasis of prostate cancer is poorly understood. In the present study, the prostate tissues of 42 patients with prostate adenocarcinoma (PCa) were used in the analysis of tumor associated macrophages (TAMs) and AAMs by immunofluorescence. The patients were followed up for 5 years. The associations of TAMs and AAMs with the clinicopathological features and outcome in these cases were evaluated. Immunofluorescent analysis indicated that the mean number of TAMs (CD68-positive cells) in the prostate tissues of PCa patients with metastasis [45.29±7.25 cells/high-power field (HPF)] was significantly higher compared with that of PCa patients without metastasis (33.57±5.25 cells/HPF; P<0.01). The mean numbers of AAMs (CD68-and CD206-positive cells) in the tissues of PCa patients with and without metastasis were 29.43±5.68 and 9.14±5.29 cells/HPF, respectively. In addition, the percentage of AAMs (number of AAMs/number of TAMs) was 65.11±9.68 and 27.32±7.85% in patients with and without metastasis, respectively. The differences in the number and percentage of AAMs between the two groups were statistically significant (P<0.01). The number and percentage of AAMs was positively correlated with tumor grade and serum prostate-specific antigen (PSA) level. Univariate analysis indicated that the level of PSA, Gleason score, metastatic status, T grade, number of TAMs, number of AAMs and percentage of AAMs were predictors of the overall survival. Furthermore, multivariate analyses revealed that Gleason score, level of PSA and number of TAMs were predictors for overall survival rate. These results indicate that TAMs and AAMs may be important in the metastasis of PCa, and that TAMs and AAMs may be used as potential biomarkers of poor prognosis in late-stage PCa patients.

show abstract

Section: A B Cmentioning

confidence: 99%

Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma

Yunjuan

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…However, no correlation has been reported between primary PSA level and OS [11][12][13][14][15][16]. Furthermore, in studies including patients with locally-advanced and metastatic prostate cancer, the primary PSA level did not independently predict TTP nor OS [11,21,23]. These findings suggest the primary PSA level may not affect OS in patients with prostate cancer treated with ADT.…”

Section: Discussionmentioning

confidence: 90%

“…In this situation, it is important to precisely evaluate the clinical efficacy of ADT consisting of traditional maximum androgen blockade (MAB) at this time. There have been several reports of outcomes from patients with prostate cancer treated with ADT [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]; however, the number of studies, that reported outcomes in patients with bone metastatic prostate cancer treated primarily with MAB without any local treatment, is limited. Recently, outcomes of MAB as an initial treatment for patients with bone metastatic prostate cancer have been reported, in which the significant impact of PSA kinetics not on OS but on disease progression was demonstrated [16].…”

Section: Open Accessmentioning

confidence: 99%

Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy

Yamamoto¹,

Nozawa²,

Itami³

et al. 2013

J Cancer Res Ther

View full text Add to dashboard Cite

“…[8][9][10][11][12][13] However, nadir PSA level and time to PSA nadir were unpredictable in initial diagnosis, and Gleason score was nonspecific for CRPC. It was known that androgen ablation provided a selective advantage to androgen-refractory cells that grow and eventually comprise most of the tumor.…”

Section: Discussionmentioning

confidence: 99%

“…Although serum prostate specific antigen (PSA) has been considered the main indicator to assess the treatment response of ADT, it must be stressed that PSA level is not a reliable marker for CRPC and could not stand alone as a follow-up test. 2,[8][9][10] Patients with Gleason score 8 to 10 took a significantly shorter time to CRPC, [11][12][13] but the significant predictive value of high Gleason grade remains controversial. Therefore, it is very desirable to predict the prognosis of patients with primary PC using new technologies on clinical practice.…”

Section: Introductionmentioning

confidence: 99%

Raman spectroscopy, a potential tool in diagnosis and prognosis of castration-resistant prostate cancer

Wang

Zeng

et al. 2013

J. Biomed. Opt

View full text Add to dashboard Cite

Abstract. Purpose: We evaluated the feasibility of Raman spectroscopy (RS) in diagnosis and prognosis of castration-resistant prostate cancer (CRPC) in patients with prostate cancer (PC). Materials and methods: Raman spectra are detected from PC cell lines (LNCaP and C4-2) and tissues using a Labram HR 800 RS. Then, principal component analysis (PCA) and support vector machine (SVM) are applied for prediction. A leave-one-out cross-validation is used to train and test the SVM. Results: There are 50 qualified patients, including 33 with androgendependent prostate cancer (ADPC) and 17 with CRPC. The spectral changes at 1126, 1170, 1315 to 1338, and 1447 cm −1 between CRPC and ADPC are detected in both cells and tissues models, which are assigned to specific amino acids and DNA. PCA/SVM algorithm provided a sensitivity of 88.2% and a specificity of 87.9% for diagnosing CRPC tissues. Furthermore, 14 patients with ADPC progressed to CRPC within 12 months. These patients are separated into two groups depending on whether their cancers progressed to CRPC within 12 months. PCA/SVM could differentiate these two groups with a sensitivity of 85.7% and a specificity of 88.9%. Conclusions: RS has the potential in diagnosis and prognosis of CRPC in clinical practice. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.

show abstract

Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy

Abstract: We concluded that both PSA nadir and time to PSA nadir are significant predictors of disease progression for prostate cancer patients receiving ADT.

Cited by 63 publications

References 42 publications

Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma

Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma

Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy

Raman spectroscopy, a potential tool in diagnosis and prognosis of castration-resistant prostate cancer

Contact Info

Product

Resources

About